TYK2 on tau

Leslie K. Ferrarelli

DOI: https://doi.org/10.1126/scisignal.adu6085

IF: 9.517

2024-11-28

Science Signaling

Abstract:The kinase TYK2 facilitates pathological tau assembly through protein-stabilizing modifications.

cell biology,biochemistry & molecular biology

What problem does this paper attempt to address?

Targeting TYK2 to target tau

Caroline Barranco

DOI: https://doi.org/10.1038/s41583-024-00890-2

IF: 38.755

2024-11-29

Nature Reviews Neuroscience

Abstract:Studies in human cell lines and transgenic mouse models show that non-receptor tyrosine-protein kinase TYK2 phosphorylates tau at Tyr29 and thereby promotes its stabilization and accumulation. In mice, knockdown of TYK2 reduced tau levels and attenuated tau neuropathology.

neurosciences
PTK2 regulates tau-induced neurotoxicity via phosphorylation of p62 at Ser403

Shinrye Lee,Myungjin Jo,Younghwi Kwon,Yu-Mi Jeon,Seyeon Kim,Kea Joo Lee,Hyung-Jun Kim

DOI: https://doi.org/10.1080/01677063.2022.2114471

2022-08-25

Journal of Neurogenetics

Abstract:Tau is a microtubule-associated protein that forms insoluble filaments that accumulate as neurofibrillary tangles in neurodegenerative diseases such as Alzheimer's disease and other related tauopathies. A relationship between abnormal Tau accumulation and ubiquitin–proteasome system impairment has been reported. However, the molecular mechanism linking Tau accumulation and ubiquitin proteasome system (UPS) dysfunction remains unclear. Here, we show that overexpression of wild-type or mutant (P301L) Tau increases the abundance of polyubiquitinated proteins and activates the autophagy–lysosome pathway in mammalian neuronal cells. Previous studies found that PTK2 inhibition mitigates toxicity induced by UPS impairment. Thus, we investigated whether PTK2 inhibition can attenuate Tau-induced UPS impairment and cell toxicity. We found that PTK2 inhibition significantly reduces Tau-induced death in mammalian neuronal cells. Moreover, overexpression of WT or mutant Tau increased the phosphorylation levels of PTK2 and p62. We also confirmed that PTK2 inhibition suppresses Tau-induced phosphorylation of PTK2 and p62. Furthermore, PTK2 inhibition significantly attenuated the climbing defect and shortened the lifespan in the Drosophila model of tauopathy. In addition, we observed that phosphorylation of p62 is markedly increased in Alzheimer's disease patients with tauopathies. Taken together, our results indicate that the UPS dysfunction induced by Tau accumulation might contribute directly to neurodegeneration in tauopathies and that PTK2 could be a promising therapeutic target for tauopathies.

genetics & heredity,neurosciences
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy

A. Harrison Brody,Sarah Helena Nies,Fulin Guan,Levi M. Smith,Bandhan Mukherjee,Santiago A. Salazar,Suho Lee,Tu Kiet T. Lam,Stephen M. Strittmatter

DOI: https://doi.org/10.1186/s13024-022-00526-y

2022-05-04

Molecular Neurodegeneration

Abstract:Background Genetic variation at the PTK2B locus encoding the protein Pyk2 influences Alzheimer's disease risk. Neurons express Pyk2 and the protein is required for Amyloid-β (Aβ) peptide driven deficits of synaptic function and memory in mouse models, but Pyk2 deletion has minimal effect on neuro-inflammation. Previous in vitro data suggested that Pyk2 activity might enhance GSK3β-dependent Tau phosphorylation and be required for tauopathy. Here, we examine the influence of Pyk2 on Tau phosphorylation and associated pathology. Methods The effect of Pyk2 on Tau phosphorylation was examined in cultured Hek cells through protein over-expression and in iPSC-derived human neurons through pharmacological Pyk2 inhibition. PS19 mice overexpressing the P301S mutant of human Tau were employed as an in vivo model of tauopathy. Phenotypes of PS19 mice with a targeted deletion of Pyk2 expression were compared with PS19 mice with intact Pyk2 expression. Phenotypes examined included Tau phosphorylation, Tau accumulation, synapse loss, gliosis, proteomic profiling and behavior. Results Over-expression experiments from Hek293T cells indicated that Pyk2 contributed to Tau phosphorylation, while iPSC-derived human neuronal cultures with endogenous protein levels supported the opposite conclusion. In vivo, multiple phenotypes of PS19 were exacerbated by Pyk2 deletion. In Pyk2-null PS19 mice, Tau phosphorylation and accumulation increased, mouse survival decreased, spatial memory was impaired and hippocampal C1q deposition increased relative to PS19 littermate controls. Proteomic profiles of Pyk2-null mouse brain revealed that several protein kinases known to interact with Tau are regulated by Pyk2. Endogenous Pyk2 suppresses LKB1 and p38 MAPK activity, validating one potential pathway contributing to increased Tau pathology. Conclusions The absence of Pyk2 results in greater mutant Tau-dependent phenotypes in PS19 mice, in part via increased LKB1 and MAPK activity. These data suggest that in AD, while Pyk2 activity mediates Aβ-driven deficits, Pyk2 suppresses Tau-related phenotypes.

neurosciences
TYK2: An Upstream Kinase of STATs in Cancer

Katharina Wöss,Natalija Simonović,Birgit Strobl,Sabine Macho-Maschler,Mathias Müller

DOI: https://doi.org/10.3390/cancers11111728

2019-11-05

Cancers

Abstract:In this review we concentrate on the recent findings describing the oncogenic potential of the protein tyrosine kinase 2 (TYK2). The overview on the current understanding of TYK2 functions in cytokine responses and carcinogenesis focusses on the activation of the signal transducers and activators of transcription (STAT) 3 and 5. Insight gained from loss-of-function (LOF) gene-modified mice and human patients homozygous for Tyk2/TYK2-mutated alleles established the central role in immunological and inflammatory responses. For the description of physiological TYK2 structure/function relationships in cytokine signaling and of overarching molecular and pathologic properties in carcinogenesis, we mainly refer to the most recent reviews. Dysregulated TYK2 activation, aberrant TYK2 protein levels, and gain-of-function (GOF) TYK2 mutations are found in various cancers. We discuss the molecular consequences thereof and briefly describe the molecular means to counteract TYK2 activity under (patho-)physiological conditions by cellular effectors and by pharmacological intervention. For the role of TYK2 in tumor immune-surveillance we refer to the recent Special Issue of Cancers “JAK-STAT Signaling Pathway in Cancer”.

oncology
The Non-receptor Tyrosine Kinase Pyk2 in Brain Function and Neurological and Psychiatric Diseases

Benoit de Pins,Tiago Mendes,Albert Giralt,Jean-Antoine Girault

DOI: https://doi.org/10.3389/fnsyn.2021.749001

2021-10-06

Abstract:Pyk2 is a non-receptor tyrosine kinase highly enriched in forebrain neurons. Pyk2 is closely related to focal adhesion kinase (FAK), which plays an important role in sensing cell contacts with extracellular matrix and other extracellular signals controlling adhesion and survival. Pyk2 shares some of FAK's characteristics including recruitment of Src-family kinases after autophosphorylation, scaffolding by interacting with multiple partners, and activation of downstream signaling pathways. Pyk2, however, has the unique property to respond to increases in intracellular free Ca2+, which triggers its autophosphorylation following stimulation of various receptors including glutamate NMDA receptors. Pyk2 is dephosphorylated by the striatal-enriched phosphatase (STEP) that is highly expressed in the same neuronal populations. Pyk2 localization in neurons is dynamic, and altered following stimulation, with post-synaptic and nuclear enrichment. As a signaling protein Pyk2 is involved in multiple pathways resulting in sometimes opposing functions depending on experimental models. Thus Pyk2 has a dual role on neurites and dendritic spines. With Src family kinases Pyk2 participates in postsynaptic regulations including of NMDA receptors and is necessary for specific types of synaptic plasticity and spatial memory tasks. The diverse functions of Pyk2 are also illustrated by its role in pathology. Pyk2 is activated following epileptic seizures or ischemia-reperfusion and may contribute to the consequences of these insults whereas Pyk2 deficit may contribute to the hippocampal phenotype of Huntington's disease. Pyk2 gene, PTK2B, is associated with the risk for late-onset Alzheimer's disease. Studies of underlying mechanisms indicate a complex contribution with involvement in amyloid toxicity and tauopathy, combined with possible functional deficits in neurons and contribution in microglia. A role of Pyk2 has also been proposed in stress-induced depression and cocaine addiction. Pyk2 is also important for the mobility of astrocytes and glioblastoma cells. The implication of Pyk2 in various pathological conditions supports its potential interest for therapeutic interventions. This is possible through molecules inhibiting its activity or increasing it through inhibition of STEP or other means, depending on a precise evaluation of the balance between positive and negative consequences of Pyk2 actions.
TYK2 as a novel therapeutic target in Alzheimer Disease

Laura Konig,Steve Rodriguez,Clemens Hug,Shayda Daneshvari,Alexander Chung,Gary Bradshaw,Asli Sahin,George Zhou,Robyn Eisert,Federica Piccioni,Sudeshna Das,Marian Kalocsay,Artem Sokolov,Peter Sorger,David Root,Mark W. Albers

DOI: https://doi.org/10.1101/2024.06.04.595773

2024-06-06

Abstract:Neuroinflammation is a pathological feature of many neurodegenerative diseases, including Alzheimer disease (AD) and amyotrophic lateral sclerosis (ALS), raising the possibility of common therapeutic targets. We previously established that cytoplasmic double-stranded RNA (cdsRNA) is spatially coincident with cytoplasmic pTDP-43 inclusions in neurons of patients with C9ORF72-mediated ALS4. CdsRNA triggers a type-I interferon (IFN-I)-based innate immune response in human neural cells, resulting in their death 4. Here, we report that cdsRNA is also spatially coincident with pTDP-43 cytoplasmic inclusions in brain cells of patients with AD pathology and that type-I interferon response genes are significantly upregulated in brain regions affected by AD. We updated our machine-learning pipeline DRIAD-SP (Drug Repurposing In Alzheimer Disease with Systems Pharmacology) to incorporate cryptic exon (CE) detection as a proxy of pTDP-43 inclusions and demonstrated that the FDA-approved JAK inhibitors baricitinib and ruxolitinib that block interferon signaling show a protective signal only in cortical brain regions expressing multiple CEs. Furthermore, the JAK family member TYK2 was a top hit in a CRISPR screen of cdsRNA-mediated death in differentiated human neural cells. The selective TYK2 inhibitor deucravacitinib, an FDA-approved drug for psoriasis, rescued toxicity elicited by cdsRNA. Finally, we identified CCL2, CXCL10, and IL-6 as candidate predictive biomarkers for cdsRNA-related neurodegenerative diseases. Together, we find parallel neuroinflammatory mechanisms between TDP-43 associated-AD and ALS and nominate TYK2 as a possible disease-modifying target of these incurable neurodegenerative diseases.

Neuroscience
TYK2 as a novel therapeutic target in Alzheimer's Disease with TDP-43 inclusions

Laura E König,Steve Rodriguez,Clemens Hug,Shayda Daneshvari,Alexander Chung,Gary A Bradshaw,Asli Sahin,George Zhou,Robyn J Eisert,Federica Piccioni,Sudeshna Das,Marian Kalocsay,Artem Sokolov,Peter Sorger,David E Root,Mark W Albers

DOI: https://doi.org/10.1101/2024.06.04.595773

2024-06-06

bioRxiv

Abstract:Neuroinflammation is a pathological feature of many neurodegenerative diseases, including Alzheimer's disease (AD)1,2 and amyotrophic lateral sclerosis (ALS)3, raising the possibility of common therapeutic targets. We previously established that cytoplasmic double-stranded RNA (cdsRNA) is spatially coincident with cytoplasmic pTDP-43 inclusions in neurons of patients with C9ORF72-mediated ALS4. CdsRNA triggers a type-I interferon (IFN-I)-based innate immune response in human neural cells, resulting in their death4. Here, we report that cdsRNA is also spatially coincident with pTDP-43 cytoplasmic inclusions in brain cells of patients with AD pathology and that type-I interferon response genes are significantly upregulated in brain regions affected by AD. We updated our machine-learning pipeline DRIAD-SP (Drug Repurposing In Alzheimer's Disease with Systems Pharmacology) to incorporate cryptic exon (CE) detection as a proxy of pTDP-43 inclusions and demonstrated that the FDA-approved JAK inhibitors baricitinib and ruxolitinib that block interferon signaling show a protective signal only in cortical brain regions expressing multiple CEs. Furthermore, the JAK family member TYK2 was a top hit in a CRISPR screen of cdsRNA-mediated death in differentiated human neural cells. The selective TYK2 inhibitor deucravacitinib, an FDA-approved drug for psoriasis, rescued toxicity elicited by cdsRNA. Finally, we identified CCL2, CXCL10, and IL-6 as candidate predictive biomarkers for cdsRNA-related neurodegenerative diseases. Together, we find parallel neuroinflammatory mechanisms between TDP-43 associated-AD and ALS and nominate TYK2 as a possible disease-modifying target of these incurable neurodegenerative diseases.
Tau forms oligomeric complexes on microtubules that are distinct from pathological oligomers in disease

M. T. Gyparaki,A. Arab,E. M. Sorokina,A. N. Santiago-Ruiz,C. H. Bohrer,J. Xiao,M. Lakadamyali

DOI: https://doi.org/10.1101/2020.07.07.192146

2020-07-08

Abstract:Abstract Tau is a microtubule-associated protein, which promotes neuronal microtubule assembly and stability. Accumulation of tau into insoluble aggregates known as neurofibrillary tangles (NFTs) is a pathological hallmark of several neurodegenerative diseases. The current hypothesis is that small, soluble oligomeric tau species preceding NFT formation cause toxicity. However, thus far visualizing the spatial distribution of tau monomers and oligomers inside cells under physiological or pathological conditions has not been possible. Here, using single molecule localization microscopy (SMLM), we show that, in vivo , tau forms small oligomers on microtubules under physiological conditions. These physiological oligomers are distinct from those found in cells exhibiting tau aggregation and could be pre-cursors of aggregated tau in pathology. Further, using an unsupervised shape classification algorithm that we developed, we show that different tau phosphorylation states are associated with distinct tau aggregate species. Our work elucidates tau’s nanoscale composition under physiological and pathological conditions in vivo .
Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors

Si-Shi Du,Yu-Qing Fang,Wen Zhang,Guo-Wu Rao

DOI: https://doi.org/10.2174/0929867330666230324163414

IF: 4.74

2023-03-24

Current Medicinal Chemistry

Abstract:TYK2 (tyrosine-protein kinase 2) is a non-receptor protein kinase belonging to the JAK family and is closely associated with various diseases, such as psoriasis, inflammatory bowel disease, systemic lupus erythematosus. TYK2 activates the downstream proteins STAT1-5 by participating in the signal transduction of immune factors such as IL-12, IL-23, and IL-10, resulting in immune expression. The activity of the inhibitor TYK2 can effectively block the transduction of excessive immune signals and treat diseases. TYK2 inhibitors are divided into two types of inhibitors according to the different binding sites. One is a TYK2 inhibitor that binds to JH2 and inhibits its activity through an allosteric mechanism. The representative inhibitor is BMS-986165, developed by Bristol-Myers Squibb. The other class binds to the JH1 adenosine triphosphate (ATP) site and prevents the catalytic activity of the kinase by blocking ATP and downstream phosphorylation. This paper mainly introduces the protein structure, signaling pathway, synthesis, structure-activity relationship and clinical research of TYK2 inhibitors.

pharmacology & pharmacy,biochemistry & molecular biology,chemistry, medicinal
Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Jun Yin

DOI: https://doi.org/10.1016/j.jalz.2009.04.477

2009-01-01

Abstract:Two major neuropathological features of Alzheimer's disease (AD) are intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated microtubule-associated protein tau, and the extracellular senile plaques composed of β-amyloid (Aβ). Though exposing to a proapoptotic environment, most NFTs-bearing nourons degenerate chronically rather than go to apoptosis in AD patients and other taupathies, and the mechanisms are still elusive. Recently, we have found that tau hyperphosphorylation plays a role in anti-apoptosis of the cells. The mouse Neuroblastoma 2a (N2a) cells were transfected transiently with human tau (PCI-tau40) or vector (PCI) for 24 h, then the cells were cultured with serum free medium for another 24 h (starvation). The N2a cells overexpressing tau were more resistent to serum withdrawal-induced apoptosis. The protective effect was positively correlated with the relatively increased phosphrylation level of tau. We also found that the Akt was activated in cells overexpressing tau. Simultaneously, the phosphorylation level of FOXO3 increased (representing decreased activity) and the expression of p53 and Bax decreased. The antiapoptotic effects of tau almost disappeared by inhibition of Akt. Upon serum starvation, the expression level of catalytic subunit of PI3K (p110) increased significantly in cells overexpressing tau, whereas the relative level of the phosphorylated p85 was not changed. Our findings suggest that tau leads the cells to escape apoptosis by activating PI3K/Akt pathway and the activation of PI3K.
Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent inflammatory responses

David Klenerman,Jonathan Meng,Yu Zhang,Dominik Saman,Suman De,Jason Sang,Kun Jiang,Jane Humphrey,Linda Julian,Eric Hidari,R. Andres Floto,Steven Lee,Clare Bryant,Justin Benesch,Yu Ye

DOI: https://doi.org/10.21203/rs.3.rs-374549/v1

2021-04-15

Abstract:Abstract Soluble aggregates of the microtubule-associated protein tau have been challenging to assemble and characterize, despite their important role in the development of tauopathies. We found that sequential hyperphosphorylation by PKA in conjugation with either GSK3-β or SAPK4 enabled recombinant wild-type (WT) tau of isoform 0N4R to spontaneously polymerize into small amorphous aggregates in vitro. We employed tandem mass spectrometry to determine the phosphorylation sites and the degree of phosphorylation, and super-resolution microscopy and electron microscopy to characterize the morphology of aggregates formed. Functionally, in comparison with the unmodified aggregates, which require heparin induction to assemble, these self-assembled hyperphosphorylated tau aggregates more efficiently disrupt membrane bilayers and induce Toll-like receptor 4 (TLR4)-dependent inflammatory responses. Together, our results demonstrate that tau hyperphosphorylation is potentially damaging to cells, providing a mechanistic model of how hyperphosphorylation of tau aggregates drives neuroinflammation in tauopathies.
Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates

François-Xavier Cantrelle,Anne Loyens,Xavier Trivelli,Oliver Reimann,Clément Despres,Neha S. Gandhi,Christian P. R. Hackenberger,Isabelle Landrieu,Caroline Smet-Nocca

DOI: https://doi.org/10.3389/fnmol.2021.661368

2021-06-17

Frontiers in Molecular Neuroscience

Abstract:Phosphorylation of the neuronal microtubule-associated Tau protein plays a critical role in the aggregation process leading to the formation of insoluble intraneuronal fibrils within Alzheimer’s disease (AD) brains. In recent years, other posttranslational modifications (PTMs) have been highlighted in the regulation of Tau (dys)functions. Among these PTMs, the O -β-linked N-acetylglucosaminylation ( O -GlcNAcylation) modulates Tau phosphorylation and aggregation. We here focus on the role of the PHF-1 phospho-epitope of Tau C-terminal domain that is hyperphosphorylated in AD (at pS396/pS404) and encompasses S400 as the major O -GlcNAc site of Tau while two additional O -GlcNAc sites were found in the extreme C-terminus at S412 and S413. Using high resolution NMR spectroscopy, we showed that the O -GlcNAc glycosylation reduces phosphorylation of PHF-1 epitope by GSK3β alone or after priming by CDK2/cyclin A. Furthermore, investigations of the impact of PTMs on local conformation performed in small peptides highlight the role of S404 phosphorylation in inducing helical propensity in the region downstream pS404 that is exacerbated by other phosphorylations of PHF-1 epitope at S396 and S400, or O -GlcNAcylation of S400. Finally, the role of phosphorylation and O -GlcNAcylation of PHF-1 epitope was probed in in-vitro fibrillization assays in which O -GlcNAcylation slows down the rate of fibrillar assembly while GSK3β phosphorylation stimulates aggregation counteracting the effect of glycosylation.

neurosciences
β-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates

Jung-A A. Woo,Tian Liu,Cenxiao C. Fang,Maria A. Castaño,Teresa Kee,Ksenia Yrigoin,Yan Yan,Sara Cazzaro,Jenet Matlack,Xinming Wang,Xingyu Zhao,David E. Kang,Stephen B. Liggett

DOI: https://doi.org/10.1073/pnas.1917194117

IF: 11.1

2020-02-18

Proceedings of the National Academy of Sciences

Abstract:Significance Frontotemporal lobar degeneration (FTLD) is second only to Alzheimer’s disease as a cause of dementia, and we find the scaffolding protein β-arrestin2 is elevated in human brains with this condition, and is responsible for accumulation of pathological tau tangles. Increased β-arrestin2 impairs tau clearance and promotes tau aggregation by impeding the autophagy cargo carrier p62/SQSTM1. Such activity requires β-arrestin2 in its oligomeric form, an assembly state that is not involved with receptor binding. Virus delivered gene therapy to the brain with dominant-negative mutant β-arrestin2s ablates pathologic tau in neurons of a mouse model of FTLD-tau, revealing a strategy to mitigate tauopathy by targeting β-arrestin2 oligomerization.
Srpk2 Phosphorylates Tau and Mediates the Cognitive Defects in Alzheimer'S Disease

Yi Hong,Chi Bun Chan,Il-Sun Kwon,Xuekun Li,Mingke Song,Hyun-Pil Lee,Xia Liu,Pradoldej Sompol,Peng Jin,Hyoung-gon Lee,Shan Ping Yu,Keqiang Ye

DOI: https://doi.org/10.1523/jneurosci.3300-12.2012

2012-01-01

Journal of Neuroscience

Abstract:Serine-arginine protein kinases 2 (SRPK2) is a cell cycle-regulated kinase that phosphorylates serine/arginine domain-containing proteins and mediates pre-mRNA splicing with unclear function in neurons. Here, we show that SRPK2 phosphorylates tau on S214, suppresses tau-dependent microtubule polymerization, and inhibits axonal elongation in neurons. Depletion of SRPK2 in dentate gyrus inhibits tau phosphorylation in APP/PS1 mouse and alleviates the impaired cognitive behaviors. The defective LTP in APP/PS1 mice is also improved after SRPK2 depletion. Moreover, active SRPK2 is increased in the cortex of APP/PS1 mice and the pathological structures of human Alzheimer's disease (AD) brain. Therefore, our study suggests SRPK2 may contribute to the formation of hyperphosphorylated tau and the pathogenesis of AD.
Structural determinants for activation of the Tau kinase CDK5 by the serotonin receptor 5-HT7R

Jana Ackmann,Alina Brüge,Lizaveta Gotina,Sungsu Lim,Kathrin Jahreis,Anna-Lena Vollbrecht,Yun Kyung Kim,Ae Nim Pae,Josephine Labus,Evgeni Ponimaskin

DOI: https://doi.org/10.1186/s12964-024-01612-y

IF: 7.525

2024-04-20

Cell Communication and Signaling

Abstract:Multiple neurodegenerative diseases are induced by the formation and deposition of protein aggregates. In particular, the microtubule-associated protein Tau leads to the development of so-called tauopathies characterized by the aggregation of hyperphosphorylated Tau within neurons. We recently showed that the constitutive activity of the serotonin receptor 7 (5-HT7R) is required for Tau hyperphosphorylation and aggregation through activation of the cyclin-dependent kinase 5 (CDK5). We also demonstrated physical interaction between 5-HT7R and CDK5 at the plasma membrane suggesting that the 5-HT7R/CDK5 complex is an integral part of the signaling network involved in Tau-mediated pathology.

cell biology
Tau in physiology and pathology

Yipeng Wang,Eckhard Mandelkow

DOI: https://doi.org/10.1038/nrn.2015.1

IF: 38.755

2015-12-03

Nature Reviews Neuroscience

Abstract:Key PointsTauopathies are classified into several groups based on the isoform composition of tau aggregates. The splicing of the gene encoding tau is regulated by multiple factors besides tau mutations.Tau is a natively unfolded protein that shows no tendency for aggregation by itself. Post-translational modifications may modify the processes of tau oligomerization, aggregation and tau-induced neurodegeneration.The polarized distribution of tau into the axonal compartment of neurons is determined by multiple mechanisms. In addition, part of tau is actively released into extracellular space.Besides stabilizing microtubules, regulating their dynamic instability and supporting axonal transport, tau can interact with various cell components and thus serves other functions in various other processes, including neuronal activity, neurogenesis, iron export and long-term depression.Pathological tau may induce neurotoxicity owing to its loss of function, toxic gain of function or its mislocalization, which mediates amyloid-β-induced toxicity.Several tau- or microtubule-based therapeutic approaches have been proposed, including tau aggregation inhibitors, inhibitors of kinases targeting tau, inhibition of tau acetylation, stabilization of microtubules, reduction of tau by antisense oligonucleotides, and immunotherapy using antibodies against tau or phosphorylated tau.

neurosciences
Acetylation encodes Tau aggregation

Youqi Tao,Dan Li

DOI: https://doi.org/10.1016/j.str.2023.08.002

IF: 5.871

2023-09-01

Structure

Abstract:Post-translational modifications profoundly influence amyloid assembly. In this issue of Structure, Li et al. unravel the underlying mechanism by which specific lysine acetylation patterns facilitate fibril formation of Tau segments. Their cryo-electron microscopy structure further elucidates how acetyl groups act as stabilizers within the architecture of Tau fibrils.

cell biology,biochemistry & molecular biology,biophysics
Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses

Jonathan X. Meng,Yu Zhang,Dominik Saman,Arshad M. Haider,Suman De,Jason C. Sang,Karen Brown,Kun Jiang,Jane Humphrey,Linda Julian,Eric Hidari,Steven F. Lee,Gabriel Balmus,R. Andres Floto,Clare E. Bryant,Justin L. P. Benesch,Yu Ye,David Klenerman

DOI: https://doi.org/10.1038/s41467-022-30461-x

IF: 16.6

2022-05-16

Nature Communications

Abstract:Abstract Soluble aggregates of the microtubule-associated protein tau have been challenging to assemble and characterize, despite their important role in the development of tauopathies. We found that sequential hyperphosphorylation by protein kinase A in conjugation with either glycogen synthase kinase 3β or stress activated protein kinase 4 enabled recombinant wild-type tau of isoform 0N4R to spontaneously polymerize into small amorphous aggregates in vitro. We employed tandem mass spectrometry to determine the phosphorylation sites, high-resolution native mass spectrometry to measure the degree of phosphorylation, and super-resolution microscopy and electron microscopy to characterize the morphology of aggregates formed. Functionally, compared with the unmodified aggregates, which require heparin induction to assemble, these self-assembled hyperphosphorylated tau aggregates more efficiently disrupt membrane bilayers and induce Toll-like receptor 4-dependent responses in human macrophages. Together, our results demonstrate that hyperphosphorylated tau aggregates are potentially damaging to cells, suggesting a mechanism for how hyperphosphorylation could drive neuroinflammation in tauopathies.

multidisciplinary sciences
Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes

Max Stevenson,Norah K Algarzae,Charbel Moussa

DOI: https://doi.org/10.3389/frdem.2024.1458038

2024-08-16

Abstract:Tyrosine kinases (TKs) are catalytic enzymes activated by auto-phosphorylation that function by phosphorylating tyrosine residues on downstream substrates. Tyrosine kinase inhibitors (TKIs) have been heavily exploited as cancer therapeutics, primarily due to their role in autophagy, blood vessel remodeling and inflammation. This suggests tyrosine kinase inhibition as an appealing therapeutic target for exploiting convergent mechanisms across several neurodegenerative disease (NDD) pathologies. The overlapping mechanisms of action between neurodegeneration and cancer suggest that TKIs may play a pivotal role in attenuating neurodegenerative processes, including degradation of misfolded or toxic proteins, reduction of inflammation and prevention of fibrotic events of blood vessels in the brain. In this review, we will discuss the distinct roles that select TKs have been shown to play in various disease-associated processes, as well as identify TKs that have been explored as targets for therapeutic intervention and associated pharmacological agents being investigated as treatments for NDDs.
The E3 Ubiquitin Ligase, CHIP/STUB1, Inhibits Aggregation of Phosphorylated Proteoforms of Microtubule-associated Protein Tau (MAPT)

Cory M Nadel,Aye C Thwin,Matthew Callahan,Kanghyun Lee,Emily Connelly,Charles S Craik,Daniel R Southworth,Jason E Gestwicki

DOI: https://doi.org/10.1016/j.jmb.2023.168026

2023-06-01

Abstract:Hyper-phosphorylated tau accumulates as insoluble fibrils in Alzheimer's disease (AD) and related dementias. The strong correlation between phosphorylated tau and disease has led to an interest in understanding how cellular factors discriminate it from normal tau. Here, we screen a panel of chaperones containing tetratricopeptide repeat (TPR) domains to identify those that might selectively interact with phosphorylated tau. We find that the E3 ubiquitin ligase, CHIP/STUB1, binds 10-fold more strongly to phosphorylated tau than unmodified tau. The presence of even sub-stoichiometric concentrations of CHIP strongly suppresses aggregation and seeding of phosphorylated tau. We also find that CHIP promotes rapid ubiquitination of phosphorylated tau, but not unmodified tau, in vitro. Binding to phosphorylated tau requires CHIP's TPR domain, but the binding mode is partially distinct from the canonical one. In cells, CHIP restricts seeding by phosphorylated tau, suggesting that it could be an important barrier in cell-to-cell spreading. Together, these findings show that CHIP recognizes a phosphorylation-dependent degron on tau, establishing a pathway for regulating the solubility and turnover of this pathological proteoform.

TYK2 on tau

Targeting TYK2 to target tau

PTK2 regulates tau-induced neurotoxicity via phosphorylation of p62 at Ser403

Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy

TYK2: An Upstream Kinase of STATs in Cancer

The Non-receptor Tyrosine Kinase Pyk2 in Brain Function and Neurological and Psychiatric Diseases

TYK2 as a novel therapeutic target in Alzheimer Disease

TYK2 as a novel therapeutic target in Alzheimer's Disease with TDP-43 inclusions

Tau forms oligomeric complexes on microtubules that are distinct from pathological oligomers in disease

Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent inflammatory responses

Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates

β-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates

Srpk2 Phosphorylates Tau and Mediates the Cognitive Defects in Alzheimer'S Disease

Structural determinants for activation of the Tau kinase CDK5 by the serotonin receptor 5-HT7R

Tau in physiology and pathology

Acetylation encodes Tau aggregation

Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses

Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes

The E3 Ubiquitin Ligase, CHIP/STUB1, Inhibits Aggregation of Phosphorylated Proteoforms of Microtubule-associated Protein Tau (MAPT)